drugset / Trial / NCT01839552

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.

NCT01839552 ↗

NaSingle-groupOpen-labelSupportive care

Summary

Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking other opioid pain medicines and the patient's body has become used to them (opioid tolerant). The purpose of this study is to assess the ability of Lazanda to control pain during an episode of breakthrough pain in cancer patients.

Timeline

Start
2014-10
Primary completion
2017-04
Completion
2018-04

Outcome

Outcome not reported

Stopped (Enrollment): “Site chose to close due to lack of enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified — Intranasal

Indications

No indication recorded.